The use of Fst-288 as a potential therapeutic (to bind
and counteract effects of myostatin or Activin A) is therefore
particularly attractive, especially given the capacity for Fst-288
to remain restricted to the tissue in which it is expressed/introduced
(in this case, constraining the effect of the intervention
to skeletal muscle)